We are live on ! Find out more
BSX icon

Boston Scientific

843 hedge funds and large institutions have $50B invested in Boston Scientific in 2020 Q3 according to their latest regulatory filings, with 80 funds opening new positions, 326 increasing their positions, 302 reducing their positions, and 73 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more capital invested

Capital invested by funds: $45.8B → $50B (+$4.19B)

10% more first-time investments, than exits

New positions opened: 80 | Existing positions closed: 73

8% more repeat investments, than reductions

Existing positions increased: 326 | Existing positions reduced: 302

0% more funds holding

Funds holding: 840843 (+3)

0.29% more ownership

Funds ownership: 91.34%91.63% (+0.29%)

18% less funds holding in top 10

Funds holding in top 10: 1714 (-3)

65% less call options, than puts

Call options by funds: $119M | Put options by funds: $338M

Holders
843
Holders Change
+3
Holders Change %
+0.36%
% of All Funds
17.01%
Holding in Top 10
14
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-17.65%
% of All Funds
0.28%
New
80
Increased
326
Reduced
302
Closed
73
Calls
$119M
Puts
$338M
Net Calls
-$218M
Net Calls Change
-$63.2M
Name Holding Trade Value Shares
Change
Change in
Stake
BOM
501
Bank of Marin
California
$669K -$4.43K -115 -0.7%
VAS
502
Vestmark Advisory Solutions
Massachusetts
$669K +$83K +2,154 +14%
FAAS
503
First Allied Advisory Services
California
$666K +$1.35K +35 +0.2%
PCM
504
Prelude Capital Management
New York
$661K -$1.62M -41,933 -71%
SPIA
505
Steward Partners Investment Advisory
New York
$661K +$74.9K +1,943 +13%
ICM
506
Islay Capital Management
Texas
$659K -$66.7K -1,731 -9%
NICM
507
Neo Ivy Capital Management
New York
$652K +$137K +3,544 +26%
AAS
508
Avantax Advisory Services
Texas
$649K +$94.6K +2,454 +17%
ECM
509
ExodusPoint Capital Management
New York
$639K -$4.69M -121,691 -88%
FHA
510
Flagship Harbor Advisors
Massachusetts
$629K -$26K -676 -4%
ETC
511
Exchange Traded Concepts
Oklahoma
$621K +$254K +6,589 +68%
KA
512
Kintegral Advisory
New York
$608K -$19.7K -512 -3%
SCA
513
Snowden Capital Advisors
New York
$605K +$16.5K +427 +3%
Mariner
514
Mariner
Kansas
$603K -$63.1K -1,637 -9%
HCP
515
Hexagon Capital Partners
Arkansas
$601K +$671K +17,416 New
GTCM
516
Gyon Technologies Capital Management
New Jersey
$598K +$9.6K +249 +2%
MFG
517
MidWestOne Financial Group
Iowa
$595K -$102K -2,638 -14%
CCM
518
Carlson Capital Management
Minnesota
$595K -$20K -520 -3%
PFGIA
519
Patriot Financial Group Insurance Agency
Massachusetts
$592K +$405K +10,514 +212%
CAPTRUST Financial Advisors
520
CAPTRUST Financial Advisors
North Carolina
$586K +$134K +3,478 +30%
CFGS
521
Concourse Financial Group Securities
Alabama
$576K +$51.7K +1,341 +10%
IC
522
IEQ Capital
California
$575K +$289K +7,488 +99%
LS
523
Livforsakringsbolaget Skandia
Sweden
$563K
FHB
524
First Hawaiian Bank
Hawaii
$562K -$39.8K -1,033 -7%
DC
525
Davenport & Co
Virginia
$561K -$22.9K -595 -4%

BSX Hedge Fund Activity: Q3 2020 in Review

843 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Boston Scientific (BSX) for Q3 2020, worth a combined $50B — up 9.1% from $45.8B a quarter earlier.

Buyers outnumbered sellers: 80 funds opened new BSX positions and 73 closed out — a net gain of 7 holders — while 326 added to existing stakes and 302 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $524M. The largest seller was Capital World Investors, cutting an estimated $895M.

  • 843 institutional investors held Boston Scientific (BSX) as of Q3 2020, up from 840 in Q2 2020.
  • Funds reported $50B of Boston Scientific stock for Q3 2020, up 9.1% quarter-over-quarter.
  • 80 funds opened new Boston Scientific positions in Q3 2020 and 73 closed out, a net change of +7 holders.
  • The largest Boston Scientific buyer in Q3 2020 was T. Rowe Price Associates, an estimated $524M added.
  • The largest Boston Scientific seller in Q3 2020 was Capital World Investors, an estimated $895M sold.

Based on aggregated 13F filings for Q3 2020.